MOUMITA KUNDU

Dr. MOUMITA KUNDU

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Chemical Engineering Journal
Verified
Journal Article
Closed access
SBSovan Lal Banerjee
Sovan Lal Banerjee
SDSubhayan Das
Subhayan Das
KBKoushik Bhattacharya
Koushik Bhattacharya
MKMOUMITA KUNDU
MOUMITA KUNDU
MMMahitosh Mandal
Mahitosh Mandal
NSNikhil K. Singha
Nikhil K. Singha

29 July 2019 in Phytotherapy Research
Verified
Journal Article
Closed access
MKMOUMITA KUNDU
MOUMITA KUNDU
SDSubhayan Das
Subhayan Das
DDDibakar Dhara
Dibakar Dhara
MMMahitosh Mandal
Mahitosh Mandal

20 July 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
ASAmit Kumar Singh
Amit Kumar Singh
MKMOUMITA KUNDU
MOUMITA KUNDU
SRSamrat Roy
Samrat Roy
BRBiswajit Roy
Biswajit Roy
SSSk. Sheriff Shah
Sk. Sheriff Shah
NSN. D. Pradeep Singh
N. D. Pradeep Singh
We report a two-photon responsive drug delivery system (DDS), namely, p-hydroxyphenacyl–naphthalene–chlorambucil (pHP–Naph–Cbl), having a two-photon absorption (TPA) cross-section of ≥20 GM in the phototherapeutic window (700 nm). Our DDS exhibited both AIE and ESIPT phenomena, which were utilized for the real-time monitoring of anti-cancer drug release.

2 February 2022 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Verified
Journal Article
Closed access
ADAnkita Dey
Ankita Dey
MKMOUMITA KUNDU
MOUMITA KUNDU
SDSubhayan Das
Subhayan Das
BJBikash Chandra Jena
Bikash Chandra Jena
MMMahitosh Mandal
Mahitosh Mandal

30 May 2025 in Discover Oncology
Verified
Journal Article
Open access
PDF file
SDSubhayan Das
Subhayan Das
SGShayeri Chatterjee Ganguly
Shayeri Chatterjee Ganguly
SBShiuli Bera
Shiuli Bera
MKMOUMITA KUNDU
MOUMITA KUNDU
Prostate cancer is the second leading malignancy in males. Prostate cancer can be easily curable if it is diagnosed at an early stage. The prognosis of pat

28 July 2025 in Discover Oncology
Verified
Journal Article
Open access
IDIshita Debnath
Ishita Debnath
MKMOUMITA KUNDU
MOUMITA KUNDU
Cancer stem cells (CSCs) are a specific subset of cancer cells that possess the ability to self-renew, resist therapies, and promote metastasis, making them a crucial target in cancer treatment. This study investigates the therapeutic potential of natural compounds in targeting CSCs, particularly their ability to inhibit key signaling pathways, induce apoptosis, and alter the tumor microenvironment. This article reviews the molecular mechanisms that maintain CSCs and contribute to their resistance, focusing on the roles of the WNT/β-catenin, Hedgehog, Notch, and PI3K/ATK/mTOR pathways. Several natural compounds, including curcumin, resveratrol, epigallocatechin gallate, and sulforaphane, were assessed for their effectiveness in targeting CSCs. The finding revealed that these natural compounds can inhibit CSC proliferation, enhance sensitivity to chemotherapy, and suppress the tumor-supportive microenvironment. Notably, compounds such as berberine and piperine were found to reverse drug resistance by downregulating efflux transporters, while quercetin and salinomycin selectively induced apoptosis in CSCs. Overall, natural compounds show promising potential for targeting CSCs in therapy. However, challenges related to bioavailability and metabolic stability must be addressed through advanced drug delivery systems and combination therapy.